Taho Pharmaceuticals Ltd. engages in the research and development of pharmaceutical products. Its Technology Platform products are the Transepithelial Delivery System, Transdermal DDS, Transmucosal SSD, and Bio-Revie. The firm's Research & Development products include medicines for migraine, alzheimer's disease, hyperactivity disorder, and nausea caused by chemotherapy. The company was founded on July 7, 2010 and is headquartered in Taipei, Taiwan.